Method for assessing the risk of early postoperative complications

The platelet-neutrophil ratio (TNO) method addresses the limitations of existing methods by providing a preoperative assessment of postoperative complications in gastric cancer patients, enabling accurate risk stratification and personalized treatment planning.

WO2026240679A1PCT designated stage Publication Date: 2026-11-19ROGOZIANSKAIA MARINA IGOREVNA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/RU2026/050059
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-11
Filing Date
2026-03-23
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing methods for predicting postoperative complications in gastric cancer patients after gastrectomy are labor-intensive, require complex calculations, rely on postoperative data, or are not suitable for treatment planning, and lack statistically significant predictors for stratifying patient risk groups.

Method used

A method using the platelet-neutrophil ratio (TNO) as a statistically significant predictor, calculated from preoperative hemogram results, to assess the risk of early postoperative complications, allowing for personalized treatment planning and stratification of patients into high and low risk groups.

Benefits of technology

The TNO-based method accurately predicts early postoperative complications with a high accuracy of 89.6%, enabling effective risk assessment before surgery and facilitating personalized treatment approaches.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000004_0001
    Figure IMGF000004_0001
  • Figure IMGF000005_0001
    Figure IMGF000005_0001
  • Figure IMGF000005_0002
    Figure IMGF000005_0002
Patent Text Reader

Abstract

The group of inventions relates to medicine, and more particularly to oncology and surgery, and is intended for assessing the risk of early postoperative complications after gastrectomy in patients with stomach cancer. In a first embodiment, a platelet-to-neutrophil ratio (PNR) is determined prior to commencement of treatment; if the PNR is greater than 69, the risk of complications is deemed to be high. In a second embodiment, a risk index (y) is calculated using a logistic regression equation, taking into account PNR, relative eosinophil count and depth of tumour invasion, and the probability (P) of complications is calculated taking into account the risk index (y); if P is greater than 0.5, the risk of complications is deemed to be high. The group of inventions makes it possible to more accurately assess the risk of complications at the stage of diagnosis, treatment planning and perioperative management of gastric cancer patients.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Description of the invention

[0002] The invention relates to medicine, namely to oncology and surgery, and is intended to assess the risk of developing complications in the early postoperative period after gastrectomy in patients with gastric cancer (GC).

[0003] Gastrectomy with D2 lymph node dissection remains the preferred surgical procedure for malignant tumors of the body and proximal stomach with a depth of invasion of pT2-T4a. The incidence of complications in the early postoperative period ranges from 8 to 10%, severe complications (grade III and higher according to the Clavien-Dindo classification) occur in 2.7% of patients, and the postoperative mortality rate reaches 1.15% (Sano et al., 2017, p. 280).

[0004] This determines the relevance of searching for predictors of complicated early postoperative period and the development of algorithms for perioperative patient management taking into account risk groups.

[0005] An analysis of patent sources revealed the presence of inventions related to the subject matter.

[0006] A method for predicting the development of acute postoperative pancreatitis is known [naT.RU No. 2722672], based on a scoring assessment of risk factors: the type of surgical intervention, the volume of lymph node dissection performed, the presence of background chronic pancreatitis, ulcer penetration and tumor ingrowth into the pancreas, ulcer history, duodenostasis and D-dimer levels on the first day after surgery.

[0007] Disadvantages of the method:

[0008] - risk factors and their assessment in the development of postoperative pancreatitis are determined empirically without the use of statistical methods;

[0009] - the leading factors in the development of postoperative pancreatitis are surgical interventions on the pancreas and the presence of non-neoplastic pathology of the stomach and pancreas, which makes it uninformative for patients with tumors that do not extend beyond the wall of the stomach (pT1-3) and without concomitant pathology.

[0010] A method for predicting the likelihood of complications in the early postoperative period in patients undergoing gastrectomy for gastric cancer is known [naT.RU No. 2023103186]. The risk of complications is assessed based on risk factors: tumor pathological parameters, clinical data (patient age, duration of surgery, intraoperative blood loss, and the presence of adhesions in the abdominal cavity).

[0011] Disadvantages of the method:

[0012] - the impossibility of assessing the risk of complications at the treatment planning stage, since the method is based on intraoperative data and the results of the histological report of the surgical material

[0013] - labor-intensive calculations due to the presence of a large number of factors.

[0014] A method for predicting the development of acute postoperative pancreatitis in cancer patients is known [naT.RU 2466399]. The method allows for the identification of patients predisposed to the development of acute postoperative pancreatitis after gastrectomy with indications for splenectomy. The authors propose determining the activity of the narrow substrate specificity proteinase kallikrein and the content of its precursor prekallikrein in blood plasma 24 hours before surgery. The prekallikrein / kallikrein ratio is calculated. A value from 1.02 to 1.2 predicts the development of acute postoperative pancreatitis in days 1-8 after surgery; a value greater than 1.2 predicts a pancreatitis-free postoperative period. A disadvantage of cnocoba is the need to perform an enzyme-linked immunosorbent assay, which is not always possible in a real-life clinical situation.

[0015] A method for predicting postoperative complications after radical operations in patients with gastric cancer is known [patent. RU K»2706696]. In the blood of patients with gastric cancer on the first day after surgery, immunological indicators of CD3, CD4, CD8 and HLA-DRpr are determined, the indicators of luminol-dependent and lucigenin-dependent chemiluminescence induced by zymosan and St. epidermidis are described: I max (sp) with lum + zym, I max (sp) with luc + zym, T max (in) with lum + st, I max (in) with lum + st, IA with lum + st, determine the immunoregulatory index (IRI), conduct a statistical analysis and derive linear discriminant functions for the absence (D1) and for the development (D2) of postoperative complications. At D1> D2, a conclusion is made about low, and at D1 <D2 - о высоком риске развития послеоперационных осложнений.

[0016] The method is labor-intensive, requiring the participation of immunoassay laboratory specialists, expensive reagents, and complex calculations. Furthermore, it relies on patients' postoperative hemograms, making it unsuitable for use during treatment planning.

[0017] The prototype of the invention was the use of the platelet-neutrophil ratio (TNR) in predicting the course of infectious and non-infectious diseases, including colorectal cancer (Morais et al., 2024, p. 2476).

[0018] The objective of the invention is to assess the risk of developing complications in the early postoperative period using statistically significant predictors, which will allow stratification of groups of patients with high and low risk of complications.

[0019] The technical result is the ability to assess the risk of developing early postoperative complications at the diagnostic and planning stage.

[0020] treatment of patients, which contributes to the implementation of a personalized approach in the treatment of gastric cancer.

[0021] The method is based on the results of observation of 85 patients with stages I-III gastric cancer (histological types: adenocarcinoma and signet-ring cell carcinoma). Before treatment, all patients were examined in accordance with the recommendations of the "Clinical Guidelines. Gastric Cancer" [developed by the All-Russian National Union "Association of Oncologists of Russia" and the All-Russian Public Organization "Russian Society of Clinical Oncology", 2020, online resource].

[0022]

[0023] After which radical surgical treatment was performed, including gastrectomy with D2 lymph node dissection, with or without splenectomy. After completion of specialized treatment, all patients were monitored. The average follow-up time in the study was 56.9±22.9 months (median=64 months).

[0024] The incidence of complications in the early postoperative period was 8.3% (II-IV classes according to the Clavien-Dindo classification, the study design excluded fatal complications). The factors for the development of complications included invasive GC (pT2-3) (relative risk (RR) 1.22; 95% confidence interval (CI): 1.0-1.49; p=0.07), metastatic involvement of regional lymph nodes (pN+) (RR 1.39; 95% CI: 1.04-1.87; p=0.04), including the lymph nodes of the splenic hilum (RR 3.35; 95% CI: 1.41-7.96; p=0.005).

[0025] When comparing the results of clinical analysis before treatment, patients with complications had lower levels of leukocytes and granulocytes than patients without complications. A decrease in the leukocyte count below 7-10 was considered an unfavorable prognostic factor. 9 / l, neutrophils below 3.4-10 9 / l (OR 2.04; 95% CI: 1.36-3.04; p=0.03) or their relative proportion in the leukocyte count below 50% (OR 3.95; 95% CI: 1.70-9.17; p=0.005), eosinophils below 0.1-10 9 / l (OR 1.81; 95% CI: 1.23-2.66; p=0.05) or below 2.6% in the leukocyte count (OR 1.55; 95% CI: 1.31-1.83; p=0.056). These changes are most accurately reflected by the hematological index TNO - the ratio of the absolute number of platelets to the absolute number of neutrophils: TNO = absolute number of platelets / absolute number of neutrophils.

[0026] The TNO value before the start of special treatment is an important predictor of the course of the early postoperative period (AUC±SE=0.722±0.078; 95%CI=0.569-0.875; p=0.046). The TNO threshold value of 69 (sensitivity 100%, specificity 50.8%; J=0.492) allows stratifying groups of patients with low risk (TNO less than 69) and high risk of complications (TNO more than 69) (OR 2.03; 95%CI: 1.57-2.64; p=0.01).

[0027] To calculate the risk indicator (y) for the development of complications in the early postoperative period in a specific patient, the logistic regression equation was used: y = -0.26 + 0.16 - Xi + 0.21 - X2 + 0.24 - X3. The values ​​of the variables in the regression equation are presented in Table 1.

[0028] Table 1 Values ​​of variables in the regression equation

[0029]

[0030] The probability (P) of developing complications is calculated using the formula: P =

[0031]

[0032]

[0033] If the probability (P) is greater than 0.5, then a high risk of complications is predicted; with P values ​​less than 0.5, it is assumed that there will be no complications.

[0034] The developed model demonstrates high accuracy of 89.6% (AUC±SE=0.933±0.032; 95%CI=0.871-0.996; sensitivity 90%, specificity 85.7%; p<0.001) in predicting the development of complications in the early postoperative period. The model is based on the results of a preoperative hemogram; the status of regional lymph nodes is not taken into account, and assessment of the depth of tumor invasion into the gastric wall plays a supporting role, which allows for assessing the risks of complications at the stage of treatment planning and preparing the patient for surgery.

[0035] The results obtained on the training set have been tested in clinical practice. Examples of implementation of the invention.

[0036] Example 1. Patient V., 55 years old, was diagnosed with poorly differentiated adenocarcinoma of the body of the stomach during examination.

[0037] Results of clinical blood analysis before surgery: hemoglobin 139 g / l, leukocytes 7.3-10 9 / l, neutrophils 4.2-10 9 / l (57%), lymphocytes 2.3-10 9 / l (31%), eosinophils 0.37-10 9 / l (5%), platelets 198-10 9 / l, ESR 7 mm / h.

[0038] The first stage involved combined extended gastrectomy with D2 lymph node dissection (without splenectomy). The surgery lasted 100 minutes, with a total intraoperative blood loss of 100 ml. The postoperative period was uneventful, and the patient was discharged from the hospital in satisfactory condition on the 13th postoperative day, after a 16-day hospital stay.

[0039] Histological examination of the surgical specimen revealed gastric adenocarcinoma with poor cohesion properties, with full-thickness wall invasion to the serous membrane (without invasive invasion), and metastases in 8 of the 21 lymph nodes examined in the greater and lesser omentum. No tumor growth was observed along the resection lines.

[0040] The final diagnosis was: RG St ShV TZYZaMO.

[0041] Postoperatively, the patient received five courses of FOLFOX chemotherapy. Subsequently, the patient remains under dynamic observation, with overall and relapse-free survival rates of 63 months.

[0042] Assessment of the risk of complications in the early postoperative period:

[0043] 1. TNO=198 / 4.4=45

[0044] The TNO index before the start of treatment is 45, which corresponds to a low risk of complications.

[0045] 2. The calculation of the probability of developing complications was made on the basis of clinical data of patient B. (Table 2).

[0046] Table 2 Clinical data of patient B.

[0047]

[0048] y=-0, 26+0, 16-1+0, 21-0+0, 24-0=-0.1

[0049]

[0050] Consequently, the probability of developing complications in the early postoperative period in patient V. was 47.5%, which corresponds to a low risk (P less than 0.5).

[0051] Example 2. Patient O., 37 years old, was examined for discoshesive adenocarcinoma of the body of the stomach. Results of a clinical blood test before surgery: hemoglobin 139 g / l, leukocytes 6.8-10 9 / l, neutrophils 3.4-10 9 / l (50%), eosinophils 0.068-10 9 / l (1%), lymphocytes 2-10 9 / l (40%), platelets 279-10 9 / l, ESR 8 mm / h.

[0052] The patient subsequently underwent surgical treatment, including a combined extended gastrectomy with D2 lymph node dissection (without splenectomy). The surgery lasted 100 minutes, with a total intraoperative blood loss of 200 ml.

[0053] In the early postoperative period, the patient developed pancreatitis complicated by bilateral pleurisy and splenic infarction. She underwent bilateral ultrasound-guided pleural puncture and received antisecretory, antibacterial, and anti-inflammatory therapy. The complications resolved with this treatment. She was discharged from the hospital in satisfactory condition on the 20th postoperative day, after a 22-day hospital stay.

[0054] Histological examination of the surgical material: discoshesive gastric adenocarcinoma with signet ring cells with invasion into the muscularis mucosa, along the resection lines and into the tissue of 17 examined lymph nodes of the lesser and greater omentum tissue without tumor growth.

[0055] The final diagnosis was: RG St IA TlaNOMO.

[0056] The patient has been under dynamic observation to date, with overall and relapse-free survival rates of 43 months.

[0057] Assessment of the risk of complications in the early postoperative period:

[0058] 1. TNO=279 / 3.4=82.06

[0059] The TNO index before the start of treatment was 82.06, which corresponds to a high risk of complications in the early postoperative period.2. The calculation of the probability of complications was made based on the clinical data of patient O. (Table 3).

[0060] Table 3 Clinical data of patient O.

[0061]

[0062] y=-0, 26+0, 16-0+0, 21-1+0, 24-1=0, 19

[0063]

[0064] Consequently, the probability of developing complications in the early postoperative period in patient O. was 54.7%, which corresponds to a high risk (P greater than 0.5).

Claims

(57) 1. A method for assessing the risk of developing early postoperative complications after gastrectomy in patients with gastric cancer, including taking venous blood from the patient before the start of antitumor treatment, determining the platelet-neutrophil ratio (PNR), calculated as the ratio of the absolute number of platelets to the absolute number of neutrophils, and if PNR is above 69, the risk of developing postoperative complications is assessed as high.

2. A method for assessing the risk of developing early postoperative complications after gastrectomy in patients with gastric cancer, including taking venous blood from the patient before the start of antitumor treatment, determining the platelet-neutrophil ratio (PNR) using the formula: PNR = [platelets, 10 9 / l] / [neutrophils, 10 9 / l], the proportion of eosinophils in the leukocyte formula (EOS), the depth of invasion of the primary tumor (pT), at which the risk indicator (y) is calculated using the logistic regression equation: y=-0.26+0.16-X1+0.21-X2+0.24-X3; Where Xi=1 if the tumor invasion depth is pT2 or pT3; and Xi=0 if the tumor invasion depth is pT1a-b or pT4a; X2=1, if EOS is less than or equal to 2.6%; and X2=0, if EOS is greater than 2.6%; X3=1, if TNO is greater than 69; and X3=0, if TNO is less than or equal to 69, the probability (P) of developing complications is calculated using the formula: P = 1 / (1 + e у ), with P greater than 0.5, the risk of complications is assessed as high; with P values ​​less than 0.5, the risk of complications in the early postoperative period is assessed as low.